<DOC>
	<DOCNO>NCT02741791</DOCNO>
	<brief_summary>To evaluate efficacy safety AXS-05 relative bupropion subject treatment resistant major depressive disorder ( MDD ) . This randomized , double-blind , active-controlled , 12-week , two-period study consist open-label , bupropion lead-in period , double-blind treatment period . The trial conduct subject treatment resistant MDD . Subjects consider treatment resistant MDD historical inadequate response 1 2 antidepressant treatment prospective inadequate response treatment bupropion open-label , lead-in period .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety AXS-05 Subjects With Treatment Resistant Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Key Currently meet DSMV criterion MDD History inadequate response 1 2 adequate antidepressant treatment Body mass index ( BMI ) 18 40 kg/m2 , inclusive Agree use adequate method contraception duration study Additional criterion may apply Key Suicide risk Treatment investigational drug within 6 month History electroconvulsive therapy ( ECT ) , vagus nerve stimulation , transcranial magnetic stimulation , experimental central nervous system treatment current episode past 6 month Pregnant , breastfeeding , plan become pregnant breastfeed study Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AXS-05</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>TRD</keyword>
	<keyword>MDD</keyword>
	<keyword>Axsome</keyword>
	<keyword>NMDA receptor</keyword>
	<keyword>Refractory depression</keyword>
	<keyword>Resistant depression</keyword>
	<keyword>Depression</keyword>
</DOC>